134 related articles for article (PubMed ID: 18024821)
1. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases.
Madhusudhana KC; Hannan SR; Williams CP; Goverdhan SV; Rennie C; Lotery AJ; Luff AJ; Newsom RS
Br J Ophthalmol; 2007 Dec; 91(12):1716-7. PubMed ID: 18024821
[No Abstract] [Full Text] [Related]
2. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab.
Lucas RS; McKee HD; Lee LR
Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
[No Abstract] [Full Text] [Related]
4. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
[TBL] [Abstract][Full Text] [Related]
5. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.
Lazic R; Gabric N
Graefes Arch Clin Exp Ophthalmol; 2007 Jan; 245(1):68-73. PubMed ID: 17111146
[TBL] [Abstract][Full Text] [Related]
6. Comparing ranibizumab with bevacizumab.
Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
[No Abstract] [Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment.
Fong KC; Kirkpatrick N; Mohamed Q; Johnston RL
Clin Exp Ophthalmol; 2008 Nov; 36(8):748-55. PubMed ID: 19128380
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
Jonas JB; Tao Y; Rensch F
Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
[No Abstract] [Full Text] [Related]
9. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
10. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
[TBL] [Abstract][Full Text] [Related]
12. Necessity of paracentesis before or after intravitreal injection of bevacizumab.
Huang WC; Lin JM; Chiang CC; Tsai YY
Arch Ophthalmol; 2008 Sep; 126(9):1314-5; author reply 1315. PubMed ID: 18779502
[No Abstract] [Full Text] [Related]
13. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA
Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
[TBL] [Abstract][Full Text] [Related]
14. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration.
Krebs I; Lie S; Stolba U; Zeiler F; Felke S; Binder S
Acta Ophthalmol; 2009 Sep; 87(6):611-7. PubMed ID: 18937801
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population.
Luu ST; Gray T; Warrier SK; Patel I; Muecke JS; Casson R; Gilhotra JS
Clin Exp Ophthalmol; 2010 Oct; 38(7):659-63. PubMed ID: 20456433
[TBL] [Abstract][Full Text] [Related]
18. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
[TBL] [Abstract][Full Text] [Related]
20. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
Retina; 2006; 26(9):994-8. PubMed ID: 17151485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
